Company intelligence
Baseimmune
Pioneering the next generation of active immunotherapies for chronic diseases
Biotechnology Research
London, GB
28 employees
Founded 2019
5 public signals
About Baseimmune
Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.
Verified activity
Signals from Baseimmune
5 published signals
Research & Knowledge
Baseimmune reported 74 patients with prodromal Alzheimer's disease dosed across 3 cohorts in a Phase 1b/2 trial of ACI-24.
Reported by Joshua Blight
Research & Knowledge
Baseimmune reported 12-month interim data from a Phase 1b/2 trial of ACI-24, an anti-amyloid beta active immunotherapy manufactured antibodies.
Reported by Joshua Blight
Presence & Recognition
Baseimmune set a target of 5,000,000 steps for the month of September for the Action for Pulmonary Fibrosis Go Your Distance challenge.
Reported by Baseimmune
Research & Knowledge
Baseimmune published an article discussing the future of AIxBio, emphasizing smart scientists, frontier models, specialist models, proprietary data, and experiments in the loop.
Reported by Joshua Blight
Research & Knowledge
Baseimmune is sharing information about idiopathic pulmonary fibrosis and setting a company step challenge for the month of September.
Reported by Baseimmune